美国MannKind Corporation 
胰岛素吸入设备生产商MannKind Corp


MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA™, is an ultra rapid-acting insulin. We have submitted a new drug application to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.

The pharmacokinetic profile of AFREZZA sets it apart from all other insulin products. AFREZZA particles dissolve upon contact with the lung surface, releasing insulin that rapidly enters the bloodstream. It achieves peak insulin levels within 12-14 minutes of administration, which more closely mimics the natural release of insulin than any other insulin preparation. In our clinical trials, we have observed that patients using the AFREZZA have achieved significant reductions in post-meal glucose excursions and significant improvements in overall glucose control, as measured in AIC levels, without the weight gain typically associated with insulin therapy.

AFREZZA utilizes our proprietary Technosphere® formulation technology, which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. With AFREZZA, we load human insulin onto the Technosphere particles; however, this technology is not limited to insulin delivery. We believe it represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Beyond convenience, we believe the key advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration.

In addition to our Technosphere platform, we are developing therapies for the treatment of different types of cancer. Our cancer immunotherapy program is advancing to Phase 2 studies in patients with advanced melanoma and we are conducting preclinical studies of a drug candidate for the treatment of certain malignancies and inflammatory diseases.